In-vivo disintegration and absorption of two fast acting aspirin tablet formulations compared to ibuprofen tablets using pharmacoscintigraphy

April 2, 2019

 

Aspirin is widely used to relieve acute pain and reduce fever and inflammation. New 500 mg and 1000 mg aspirin rapid disintegrating tablets with small active ingredient particle size and sodium carbonate excipient were developed to replace regular 500 mg aspirin tablet formulation containing starch and cellulose.

The rapid disintegrating aspirin tablets have been proven to show faster in-vitro dissolution and a shorter time to Cmax (Voelker 2012) resulting in faster pain relief (Cooper 2012). The current study correlates the site and time to complete tablet disintegration with the plasma concentration time profile, using γ-scintigraphyimaging technique. Two 400 mg ibuprofen tablet formulations (ibuprofen acid and ibuprofen lysine salt) have also been analyzed in this study.

Read the full white paper here

https://www.sciencedirect.com/science/article/pii/S1773224718311080

 

 

 

Please reload

Featured Posts

BDD Pharma secures license agreement with top pharma company for timed-release OralogiK™ technology

May 30, 2018

1/2
Please reload

Recent Posts
Please reload

Archive
Please reload

Follow Us
  • LinkedIn Social Icon
  • Twitter Basic Square

          BDD Ltd

 

CLINICAL SITE:   Bio-Images Drug Delivery Ltd

Glasgow Royal Infirmary

84 Castle St

Glasgow

G4 0SF, UK

FORMULATION SITE:  Bio-Images Drug Delivery Ltd

Bio-City Scotland

Bo'ness Road

Chapelhall, Newhouse

ML1 5UH, UK

Contact Us

T. +44 (0)141 552 8791

F. +44 (0)141 552 7752

E. enquiries@bddpharma.com

 

Social Media

  • LinkedIn - White Circle
  • Twitter - White Circle
  • YouTube - White Circle
  • Facebook - White Circle

Registered in Scotland No. 212868        Privacy Policy     Acceptable Use     Terms of Use            © 2019 BDD Limited.